Literature DB >> 11861221

Molecular aspects of scleroderma.

Maria Trojanowska1.   

Abstract

Scleroderma is a complex disease characterized by activation of the immune system, small-vessel vasculopathy, and fibrosis of the skin and other organs. This review is limited to the discussion of scleroderma fibroblast biology and the cellular and molecular mechanisms that contribute to the abnormal deposition of collagen. Selected aspects of abnormal extracellular matrix (ECM) regulation by scleroderma fibroblasts are critically reviewed. These include the role of transforming growth factor-beta (TGF-beta) and connective tissue growth factor (CTGF) and their receptors in the fibrotic process in scleroderma and the overview of the transcription factors involved in regulation of the human alpha2 (I) collagen (COL1A2) gene.

Entities:  

Mesh:

Year:  2002        PMID: 11861221     DOI: 10.2741/A798

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  11 in total

1.  Identification of an Association of TNFAIP3 Polymorphisms With Matrix Metalloproteinase Expression in Fibroblasts in an Integrative Study of Systemic Sclerosis-Associated Genetic and Environmental Factors.

Authors:  Peng Wei; Yang Yang; Xinjian Guo; Nainan Hei; Syeling Lai; Shervin Assassi; Mengyuan Liu; Filemon Tan; Xiaodong Zhou
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

2.  Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis.

Authors:  Katri Koli; Marjukka Myllärniemi; Kirsi Vuorinen; Kaisa Salmenkivi; Merja J Ryynänen; Vuokko L Kinnula; Jorma Keski-Oja
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

Review 3.  Cell-extracellular matrix interactions in normal and diseased skin.

Authors:  Fiona M Watt; Hironobu Fujiwara
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-04-01       Impact factor: 10.005

4.  Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin.

Authors:  Masahide Kubo; Joanna Czuwara-Ladykowska; Omar Moussa; Margaret Markiewicz; Edwin Smith; Richard M Silver; Stefania Jablonska; Maria Blaszczyk; Dennis K Watson; Maria Trojanowska
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

Review 5.  Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts?

Authors:  John Varga
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

6.  Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma.

Authors:  Gabriella Lakos; Shinsuke Takagawa; Shu-Jen Chen; Ahalia M Ferreira; Gangwen Han; Koichi Masuda; Xiao-Jing Wang; Luisa A DiPietro; John Varga
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

7.  The use of streptolysin o for the treatment of scars, adhesions and fibrosis: initial investigations using murine models of scleroderma.

Authors:  Stephen W Mamber; Vit Long; Ryan G Rhodes; Sunthorn Pond-Tor; Lyn R Wheeler; Kellie Fredericks; Brian Vanscoy; Jean-Frederic Sauniere; Remy Steinschneider; Jean-Claude Laurent; John McMichael
Journal:  Nonlinearity Biol Toxicol Med       Date:  2004-04

8.  Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin.

Authors:  Yoshihide Asano; Margaret Markiewicz; Masahide Kubo; Gabor Szalai; Dennis K Watson; Maria Trojanowska
Journal:  Mol Cell Biol       Date:  2008-11-10       Impact factor: 4.272

Review 9.  Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited.

Authors:  Armando Gabrielli; Silvia Svegliati; Gianluca Moroncini; Giovanni Pomponio; Mariarosaria Santillo; Enrico V Avvedimento
Journal:  Semin Immunopathol       Date:  2008-06-12       Impact factor: 11.759

10.  Vascular involvement in systemic sclerosis (scleroderma).

Authors:  Debendra Pattanaik; Monica Brown; Arnold E Postlethwaite
Journal:  J Inflamm Res       Date:  2011-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.